Long-Term Strategies in Advanced HCC

Video

Long-Term Strategies in Advanced HCC

May 2016

  • A 70-year old male with metastatic HCC involving the lung and bone confirmed by biopsy, experiencing mild bone pain
  • ECOG=1
  • Child-Pugh A
  • Therapy was initiated with sorafenib at 400 BID
  • Patient experienced grade 1 HTN and grade 1 hand-foot skin reaction, which was managed effectively

April 2017

  • Documented radiographic progression
  • Therapy with regorafenib at 160mg was initiated
  • Patient experienced grade 1 HTN, grade 2 hand-foot skin reaction
Recent Videos
Jamie L. Koprivnikar, MD, an expert on MDS
Jamie L. Koprivnikar, MD, an expert on MDS
Jamie L. Koprivnikar, MD, an expert on MDS
Jamie L. Koprivnikar, MD, an expert on MDS
Jamie L. Koprivnikar, MD, an expert on MDS
Jamie L. Koprivnikar, MD, an expert on MDS
Jamie L. Koprivnikar, MD, an expert on MDS
Jamie L. Koprivnikar, MD, an expert on MDS
Solly Chedid, MD, an expert on MDS
Solly Chedid, MD, an expert on MDS
Related Content
FDA OKs Study of Amezalpat in Frontline Liver Cancer

FDA OKs Study of Amezalpat in Frontline Liver Cancer

Jordyn Sava
November 13th 2024
Article

The FDA approved a phase 3 trial to assess amezalpat with the current standard of care in unresectable or metastatic hepatocellular carcinoma.

Read More

Tailoring Treatments to Better Outcomes in Liver Cancer

Tailoring Treatments to Better Outcomes in Liver Cancer

Jordyn Sava;Susanne G. Warner, MD
October 13th 2023
Podcast

In season 4, episode 16 of Targeted Talks, Susanne G. Warner, MD,discusses the importance of tailoring treatments for patients with liver cancer, taking into account the staging of the cancer.

Listen

FDA Receives Resubmitted NDA for Camrelizumab/Rivoceranib Combo in Unresectable HCC

FDA Receives Resubmitted NDA for Camrelizumab/Rivoceranib Combo in Unresectable HCC

Jordyn Sava
September 24th 2024
Article

A new drug application has been resubmitted to the FDA for the combination of camrelizumab and rivoceranib as a first-line treatment for unresectable hepatocellular carcinoma, following a complete response letter in May 2024.

Read More

Tremelimumab Plus Durvalumab Turns Heads With Updated Five-Year Data in uHCC

Tremelimumab Plus Durvalumab Turns Heads With Updated Five-Year Data in uHCC

Morgan Bayer
September 16th 2024
Article

The HIMALAYA study showed that the combination of tremelimumab and durvalumab significantly improved overall survival in patients with hepatocellular carcinoma.

Read More

Lenvatinib, Pembrolizumab, and TACE Demonstrate Significant Progression-Free Survival in Intermediate-Stage Hepatocellular Carcinoma

Lenvatinib, Pembrolizumab, and TACE Demonstrate Significant Progression-Free Survival in Intermediate-Stage Hepatocellular Carcinoma

Ashley Chan
September 15th 2024
Article

A combination of lenvatinib, pembrolizumab, and TACE significantly improved progression-free survival in patients with intermediate-stage hepatocellular carcinoma compared to dual placebo and TACE.

Read More

FDA Accepts Nivolumab/Ipilimumab Application for First-Line HCC Treatment

FDA Accepts Nivolumab/Ipilimumab Application for First-Line HCC Treatment

Sabrina Serani
August 21st 2024
Article

The application is supported by the phase 3 CheckMate -9DW study, and the FDA has set a target action date of April 21, 2025.

Read More